Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Lung Cancer

  Free Subscription


Articles published in Int J Radiat Oncol Biol Phys

Retrieve available abstracts of 299 articles:
HTML format



Single Articles


    December 2023
  1. SAFAVI AH, Palma DA, Giuliani ME
    Beyond the HILUS Trial: How Can We Improve the Safety of SABR for Ultracentral Thoracic Tumors?
    Int J Radiat Oncol Biol Phys. 2023;117:1232-1235.
    PubMed    


  2. SIVA S, Staehler M
    The Right Tool for the Job: The Knife, the SABR, or Fire and Ice?
    Int J Radiat Oncol Biol Phys. 2023;117:1047.
    PubMed    


  3. AHN J, Yeghiaian-Alvandi R, Hegi-Johnson F, Browne LH, et al
    SABR for Early Non-Small Cell Lung Cancer: Changes in Pulmonary Function, Dyspnea, and Quality of Life.
    Int J Radiat Oncol Biol Phys. 2023;117:1213-1221.
    PubMed     Abstract available


  4. LINDBERG S, Grozman V, Karlsson K, Onjukka E, et al
    Expanded HILUS Trial: A Pooled Analysis of Risk Factors for Toxicity From Stereotactic Body Radiation Therapy of Central and Ultracentral Lung Tumors.
    Int J Radiat Oncol Biol Phys. 2023;117:1222-1231.
    PubMed     Abstract available


  5. LEE SH, Geng H, Arnold J, Caruana R, et al
    Interpretable Machine Learning for Choosing Radiation Dose-volume Constraints on Cardio-pulmonary Substructures Associated with Overall Survival in NRG Oncology RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2023;117:1270-1286.
    PubMed     Abstract available


    November 2023
  6. MA J, Li Y, Yu H, Zhang J, et al
    The Role of Thoracic Vertebral Body Dosimetry in Minimizing Acute Hematologic Toxicities of Non-Small Cell Lung Cancer Patients Receiving Lung Radiotherapy and Immunotherapy.
    Int J Radiat Oncol Biol Phys. 2023 Nov 29:S0360-3016(23)08165.
    PubMed     Abstract available


  7. VALDES G, Scholey J, Nano T, Gennatas ED, et al
    Predicting the impact of proton beam therapy technology on pulmonary toxicities for locally advanced lung cancer patients enrolled on the Proton Collaborative Group prospective clinical trial.
    Int J Radiat Oncol Biol Phys. 2023 Nov 22:S0360-3016(23)08154.
    PubMed     Abstract available


  8. RAMESH S, Cifci A, Javeri S, Minne R, et al
    MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Nov 16:S0360-3016(23)08139.
    PubMed     Abstract available


  9. RITTER AR, Miller ED
    No Regrets About SABR for NETs.
    Int J Radiat Oncol Biol Phys. 2023;117:786.
    PubMed    


  10. OMIDI A, Weiss E, Rosu-Bubulac M, Thomas G, et al
    Quantitative analysis of radiotherapy-induced cardiac and aortic sequelae in lung cancer patients via magnetic resonance imaging: A pilot study.
    Int J Radiat Oncol Biol Phys. 2023 Nov 9:S0360-3016(23)08045.
    PubMed     Abstract available


  11. KUIPERS ME, van Doorn-Wink KCJ, Hiemstra PS, Slats AM, et al
    Predicting radiation-induced lung injury in lung cancer patients - challenges and opportunities: Predicting radiation-induced lung injury.
    Int J Radiat Oncol Biol Phys. 2023 Nov 2:S0360-3016(23)08049.
    PubMed     Abstract available


  12. HEGI-JOHNSON F, Rudd SE, Wichmann CW, Akhurst T, et al
    PD-L1 Positron Emission Tomography Imaging in Patients With Non-Small Cell Lung Cancer: Preliminary Results of the ImmunoPET Phase 0 Study.
    Int J Radiat Oncol Biol Phys. 2023;117:675-682.
    PubMed    


    October 2023
  13. GAUDREAULT M, Bucknell N, Woon B, Kron T, et al
    Dose-response relationship between radiotherapy and loss of lung perfusion comparing positron emission tomography and dual-energy computed tomography in non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Oct 30:S0360-3016(23)08047.
    PubMed     Abstract available


  14. FRIEDES C, Iocolano M, Lee SH, Li B, et al
    Patterns of Failure, Low Volume Relapse, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer Treated with Definitive Chemoradiation and Consolidation Immune Checkpoint Inhibitors: Patterns of Failure for after PACIFIC.
    Int J Radiat Oncol Biol Phys. 2023 Oct 20:S0360-3016(23)08010.
    PubMed     Abstract available


  15. EDWARDS DM, Sankar K, Alseri A, Jiang R, et al
    Pneumonitis after chemoradiation and adjuvant durvalumab in stage III non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Oct 2:S0360-3016(23)07971.
    PubMed     Abstract available


    September 2023
  16. LIU F, Ververs JD, Farris MK, William Blackstock A Jr, et al
    Optimal Radiotherapy Fractionation Regimens for Early-Stage Non-Small-Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Sep 19:S0360-3016(23)07929.
    PubMed     Abstract available


  17. MENG Y, Sun H, Wang S, Yang H, et al
    Treatment-Related Pneumonitis of EGFR Tyrosine Kinase Inhibitors Plus Thoracic Radiotherapy in Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Int J Radiat Oncol Biol Phys. 2023 Sep 14:S0360-3016(23)07917.
    PubMed     Abstract available


  18. LOK BH
    Radiation Therapy in the Molecular Era of Lung Cancer: How Best to Integrate Targeted Therapeutics With Definitive Radiation Therapy for Epidermal Growth Factor Receptor-Mutant Unresectable Stage III Non-Small Cell Lung Cancer?
    Int J Radiat Oncol Biol Phys. 2023;117:115-117.
    PubMed    


  19. OWEN D, Siva S, Salama JK, Daly M, et al
    Some Like It Hot: The Value of Dose and Hot Spots in Lung Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2023;117:1-5.
    PubMed    


  20. PELED N, Roisman LC, Levison E, Dudnik J, et al
    Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study.
    Int J Radiat Oncol Biol Phys. 2023;117:105-114.
    PubMed     Abstract available


    August 2023
  21. YEGYA-RAMAN N, Berman AT, Ciunci CA, Friedes C, et al
    Phase II trial of consolidation pembrolizumab after proton reirradiation for thoracic recurrences of non-small cell lung cancer: Pembro after PBT ReRT for NSCLC.
    Int J Radiat Oncol Biol Phys. 2023 Aug 29:S0360-3016(23)07846.
    PubMed     Abstract available


  22. SIMONE ICB, Serebrenik AA, Gore EM, Mohindra P, et al
    Multicenter Phase 1b/2a Clinical Trial of Radioprotectant BIO 300 Oral Suspension for Patients with Non-Small Cell Lung Cancer Receiving Concurrent Chemoradiotherapy.
    Int J Radiat Oncol Biol Phys. 2023 Aug 29:S0360-3016(23)07845.
    PubMed     Abstract available


  23. GUAN J, Sun K, Guerrero CA, Zheng J, et al
    A Phase 2 study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Aug 23:S0360-3016(23)07836.
    PubMed     Abstract available


  24. YEGYA-RAMAN N, Friedes C, Lee SH, Iocolano M, et al
    Pneumonitis rates before and after adoption of immunotherapy consolidation in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiation.
    Int J Radiat Oncol Biol Phys. 2023 Aug 22:S0360-3016(23)07815.
    PubMed     Abstract available


  25. HE Y, Cazoulat G, Wu C, Svensson S, et al
    Quantifying the Effect of 4-Dimensional Computed Tomography-Based Deformable Dose Accumulation on Representing Radiation Damage for Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Standard-Fractionated Intensity-Modulated Radiat
    Int J Radiat Oncol Biol Phys. 2023 Aug 7:S0360-3016(23)07648.
    PubMed     Abstract available


  26. THOMSON DJ, Henson C, Huang SH, McDowell LJ, et al
    The Interplay Between Radiation Dose, Volume, and Systemic Therapy.
    Int J Radiat Oncol Biol Phys. 2023;116:967-971.
    PubMed    


    July 2023
  27. OLIVER DE, Laborde JM, Singh DP, Milano MT, et al
    Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution Experience.
    Int J Radiat Oncol Biol Phys. 2023;116:849-857.
    PubMed     Abstract available


  28. LADBURY C, Li R, Danesharasteh A, Ertem Z, et al
    Explainable Artificial Intelligence to Identify Dosimetric Predictors of Toxicity in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Secondary Analysis of RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2023 Jul 3:S0360-3016(23)00598.
    PubMed     Abstract available


  29. SIVA S, Solomon BJ
    Metastatic Ablation in Epidermal Growth Factor Receptor Mutated Oligometastatic Non-Small Cell Lung Cancer-Upfront or Outback After Systemic Tyrosine Kinase Inhibitors?
    Int J Radiat Oncol Biol Phys. 2023;116:481-482.
    PubMed    


  30. AMINI A, Rusthoven CG
    Ablative Radiation Therapy for Oligometastatic EGFR-Mutated Non-small Cell Lung Cancer: Who, Why, When, and How?
    Int J Radiat Oncol Biol Phys. 2023;116:481.
    PubMed    


  31. VITZTHUM LK, Pollom EL
    Diverging Roads in the Management of Metastatic EGFR Mutated Non Small Cell Lung Cancer: Ablate All, None, or Some?
    Int J Radiat Oncol Biol Phys. 2023;116:479-480.
    PubMed    


  32. DE B, Andres G, Bates C, Staren E, et al
    Radiation Therapy Expenditures Through the First 8 Performance Periods of the Oncology Care Model at a Statewide Multispecialty Health System.
    Int J Radiat Oncol Biol Phys. 2023;116:491-499.
    PubMed     Abstract available


    May 2023
  33. SIMONE CB, Yegya-Raman N, Manjunath S, Verma V, et al
    Prospective Feasibility and Phase I/II Trial of Preoperative Proton Beam Therapy with Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 May 16:S0360-3016(23)00463.
    PubMed     Abstract available


  34. MORRIS BB, Hughes R, Fields EC, Sabo RT, et al
    Sociodemographic and Clinical Factors Associated With Radiation Treatment Nonadherence and Survival Among Rural and Nonrural Patients With Cancer.
    Int J Radiat Oncol Biol Phys. 2023;116:28-38.
    PubMed     Abstract available


    April 2023
  35. ZHOU R, Qiu B, Xiong M, Liu Y, et al
    Hypofractionated Radiotherapy followed by Hypofractionated Boost with weekly concurrent chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Results of A Prospective Phase II Study (GASTO-1049).
    Int J Radiat Oncol Biol Phys. 2023 Apr 25:S0360-3016(23)00384.
    PubMed     Abstract available


  36. BUCKNELL NW, Kron T, Herschtal A, Hardcastle N, et al
    Comparison of changes in pulmonary function following stereotactic body radiotherapy versus conventional 3D conformal radiotherapy for stage I and IIa non-small cell lung cancer: an analysis of the TROG 09.02 (CHISEL) phase III trial.
    Int J Radiat Oncol Biol Phys. 2023 Apr 20:S0360-3016(23)00369.
    PubMed     Abstract available


  37. WU TC, Stube A, Felix C, Oseguera D, et al
    Safety and Efficacy Results from iSABR, a Phase I Study of Stereotactic Ablative Radiotherapy (SABR) in Combination with Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer (NSCLC).
    Int J Radiat Oncol Biol Phys. 2023 Apr 4:S0360-3016(23)00325.
    PubMed     Abstract available


  38. GREER MD, Koger B, Glenn M, Kang J, et al
    Predicted Inferior Outcomes for Lung SBRT With Treatment Planning Systems That Fail Independent Phantom-Based Audits.
    Int J Radiat Oncol Biol Phys. 2023;115:1301-1308.
    PubMed     Abstract available


  39. STEINSBERGER T, Donetti M, Lis M, Volz L, et al
    Experimental Validation of a Real-Time Adaptive 4D-Optimized Particle Radiotherapy Approach to Treat Irregularly Moving Tumors.
    Int J Radiat Oncol Biol Phys. 2023;115:1257-1268.
    PubMed     Abstract available


  40. MCKENZIE E, Zhang S, Zakariaee R, Guthier CV, et al
    Left Anterior Descending Coronary Artery Radiation Dose Association With All-Cause Mortality in NRG Oncology Trial RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2023;115:1138-1143.
    PubMed     Abstract available


  41. YAMAMOTO T, Kabus S, Bal M, Keall PJ, et al
    Four-Dimensional Computed Tomography Ventilation Image-Guided Lung Functional Avoidance Radiation Therapy: A Single-Arm Prospective Pilot Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2023;115:1144-1154.
    PubMed     Abstract available


    March 2023
  42. KATZ MS, Weissferdt A, Antonoff MB
    Histologic Subtypes of Non-Small Cell Lung Cancer: Can We Further Personalize Radiation Therapy?
    Int J Radiat Oncol Biol Phys. 2023;115:906-908.
    PubMed    


  43. NGUYEN EK, Poon I, Ung YC, Tsao M, et al
    Toxicity and Efficacy of Multitarget Thoracic Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2023;115:897-905.
    PubMed     Abstract available


  44. CANGEMI M, Montico M, Trovo M, Minatel E, et al
    Emerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2023;115:608-621.
    PubMed     Abstract available


  45. JOSE SANTO R, Habraken SJM, Breedveld S, Hoogeman MS, et al
    Pencil-beam Delivery Pattern Optimization Increases Dose Rate for Stereotactic FLASH Proton Therapy.
    Int J Radiat Oncol Biol Phys. 2023;115:759-767.
    PubMed     Abstract available


  46. ZHANG Z, Wang Z, Yan M, Yu J, et al
    Radiomics and Dosiomics Signature From Whole Lung Predicts Radiation Pneumonitis: A Model Development Study With Prospective External Validation and Decision-curve Analysis.
    Int J Radiat Oncol Biol Phys. 2023;115:746-758.
    PubMed     Abstract available


    February 2023
  47. NAKAMURA M, Kageyama SI, Hirata H, Tochinai T, et al
    Detection of pretreatment circulating tumor DNA predicts recurrence after high-dose proton beam therapy for early-stage non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Feb 21:S0360-3016(23)00166.
    PubMed     Abstract available


  48. LIVERINGHOUSE CL, Mills MN, Ahmed KA, Washington IR, et al
    Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2023 Feb 14:S0360-3016(22)03689.
    PubMed     Abstract available


    January 2023
  49. SAVLA B, Hamza MA, Yacubovich D, Cobbs S, et al
    The impact of Body Mass Index (BMI) and residence in Food Priority Areas (FPAs) on patterns-of-care and cancer outcomes in patients with stage III non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2023 Jan 28:S0360-3016(23)00080.
    PubMed     Abstract available


  50. LEHRER EJ, Kowalchuk RO, Gurewitz J, Bernstein K, et al
    Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases is not associated with an increased risk of radiat
    Int J Radiat Oncol Biol Phys. 2023 Jan 20:S0360-3016(23)00057.
    PubMed     Abstract available


  51. LIVERINGHOUSE CL, Latifi K, Asous AG, Lam NB, et al
    Dose Limiting Pulmonary Toxicity in a Phase I/II Study of Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable Non-small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Jan 16:S0360-3016(23)00046.
    PubMed     Abstract available


  52. WANG Y, Zhang T, Wang J, Zhou Z, et al
    Induction Immune Checkpoint Inhibitors and Chemotherapy before Definitive Chemoradiation Therapy for Patients with Bulky Unresectable Stage III Non-small-cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Jan 6:S0360-3016(22)03693.
    PubMed     Abstract available


  53. SUR R, Pond G, Falkson C, Pan M, et al
    BRACHY: A Randomized Trial to Evaluate Symptom Improvement in Advanced Non-Small Cell Lung Cancer treated with External Beam Radiation With or Without High Dose Rate Intraluminal Brachytherapy.
    Int J Radiat Oncol Biol Phys. 2023 Jan 4:S0360-3016(22)03703.
    PubMed     Abstract available


    December 2022
  54. LI Y, Fan X, Yu Q, Zhai H, et al
    Proton and Carbon Ion Radiotherapy Decreased Severe Lymphopenia by Reducing Thoracic Vertebra and Aortic Dose in Non-small Cell Lung Cancer versus Intensity Modulated Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2022 Dec 28:S0360-3016(22)03677.
    PubMed     Abstract available


  55. FELDMAN J
    The Future of Treating Oligometastatic Lung Cancer Is Personalized Care.
    Int J Radiat Oncol Biol Phys. 2022;114:822-823.
    PubMed    


  56. SINGER L, Scholey J
    Finding Resonance: Using MRI to Improve the Care of Oligometastatic Disease.
    Int J Radiat Oncol Biol Phys. 2022;114:936-940.
    PubMed    


  57. TSAI CJ
    Moving Away From Counting the Numbers: Leveraging a Sensible Clinical Trial Design for Oligometastatic Disease and Beyond.
    Int J Radiat Oncol Biol Phys. 2022;114:846-848.
    PubMed    


  58. KATIPALLY RR, Olson AC, Chmura SJ
    Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases.
    Int J Radiat Oncol Biol Phys. 2022;114:840-842.
    PubMed    


  59. IYENGAR P
    Local Therapy for Oligometastatic Disease-Cart Before the Horse?
    Int J Radiat Oncol Biol Phys. 2022;114:836-839.
    PubMed    


  60. SHER DJ, Chen RC
    The Cost-Effectiveness of Consolidative Radiation Therapy in Oligometastatic Disease: High-Value Proposition or Wishful Thinking?
    Int J Radiat Oncol Biol Phys. 2022;114:824-826.
    PubMed    


  61. LEE JJB, Suh YJ, Oh C, Lee BM, et al
    Automated Computer-Aided Detection of Lung Nodules in Metastatic Colorectal Cancer Patients for the Identification of Pulmonary Oligometastatic Disease.
    Int J Radiat Oncol Biol Phys. 2022;114:1045-1052.
    PubMed     Abstract available


  62. BAKER S, Mou B, Jiang W, Liu M, et al
    Predictors of Early Polymetastatic Relapse After SABR for up to 5 Oligometastases: A Secondary Analysis of the Phase II SABR-5 Trial.
    Int J Radiat Oncol Biol Phys. 2022;114:856-861.
    PubMed     Abstract available


  63. CHEN H, Badellino S, Biswas T, Dagan R, et al
    Conditional Survival of Patients With Extracranial Oligometastatic Treated With Stereotactic Body Radiation Therapy: An International Consortium Study.
    Int J Radiat Oncol Biol Phys. 2022;114:902-909.
    PubMed     Abstract available


  64. SIVA S, Jones G, Bressel M, Shaw M, et al
    Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases.
    Int J Radiat Oncol Biol Phys. 2022;114:862-870.
    PubMed     Abstract available


  65. WILLMANN J, Vlaskou Badra E, Adilovic S, Christ SM, et al
    Distant Metastasis Velocity as a Novel Prognostic Score for Overall Survival After Disease Progression Following Stereotactic Body Radiation Therapy for Oligometastatic Disease.
    Int J Radiat Oncol Biol Phys. 2022;114:871-882.
    PubMed     Abstract available


  66. SHERRY AD, Bathala TK, Liu S, Fellman BM, et al
    Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND.
    Int J Radiat Oncol Biol Phys. 2022;114:910-918.
    PubMed     Abstract available


  67. VERMA V, Yegya-Raman N, Sprave T, Han G, et al
    A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases.
    Int J Radiat Oncol Biol Phys. 2022;114:977-988.
    PubMed     Abstract available


  68. CHEN H, Poon I, Atenafu EG, Badellino S, et al
    Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2022;114:892-901.
    PubMed     Abstract available


    November 2022
  69. TRAN PT, Sutera P, Phillips RM, Deek MP, et al
    From Idea to Clinical Practice: A Brief History of Oligometastatic Disease.
    Int J Radiat Oncol Biol Phys. 2022;114:576-580.
    PubMed    


  70. OLADERU OT, Yerramilli D
    Aggressive Local Control of Oligorecurrence After Oligometastasis: A Tale of Competing Risk Management.
    Int J Radiat Oncol Biol Phys. 2022;114:573-574.
    PubMed    


  71. GOODMAN CR, Strauss JB
    One Way or Another: An Oligorecurrence After an Oligometastasis of an Estrogen Receptor-Positive Breast Cancer.
    Int J Radiat Oncol Biol Phys. 2022;114:571-572.
    PubMed    


  72. NAVARRIA P, Baldaccini D, Clerici E, Marini B, et al
    Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study.
    Int J Radiat Oncol Biol Phys. 2022;114:762-770.
    PubMed     Abstract available


  73. KORPICS MC, Katipally RR, Partouche J, Cutright D, et al
    Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy.
    Int J Radiat Oncol Biol Phys. 2022;114:645-654.
    PubMed     Abstract available


  74. NEVENS D, Jongen A, Kindts I, Billiet C, et al
    Completeness of Reporting Oligometastatic Disease Characteristics in the Literature and Influence on Oligometastatic Disease Classification Using the ESTRO/EORTC Nomenclature.
    Int J Radiat Oncol Biol Phys. 2022;114:587-595.
    PubMed     Abstract available


  75. GUTKIN PM, von Eyben R, Chin A, Donaldson SS, et al
    Local Control Outcomes Using Stereotactic Body Radiation Therapy or Surgical Resection for Metastatic Sarcoma.
    Int J Radiat Oncol Biol Phys. 2022;114:771-779.
    PubMed     Abstract available


  76. MAHMOOD U, Huynh MA, Killoran JH, Qian JM, et al
    Retrospective Review of Outcomes After Radiation Therapy for Oligoprogressive Disease on Immune Checkpoint Blockade.
    Int J Radiat Oncol Biol Phys. 2022;114:666-675.
    PubMed     Abstract available


  77. ZHAI D, Huang J, Hu Y, Wan C, et al
    Ionizing Radiation-Induced Tumor Cell-Derived Microparticles Prevent Lung Metastasis by Remodeling the Pulmonary Immune Microenvironment.
    Int J Radiat Oncol Biol Phys. 2022;114:502-515.
    PubMed     Abstract available


    October 2022
  78. ARCIDIACONO F, Anselmo P, Casale M, Zannori C, et al
    STereotactic Ablative RadioTherapy in NEWly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrEnt RAdio-chemotherapy: early analysis of the START-NEW-ERA non-randomised phase II trial.
    Int J Radiat Oncol Biol Phys. 2022 Oct 23. pii: S0360-3016(22)03459.
    PubMed     Abstract available


  79. KIM YH, Ahn SJ, Moon SH, Kim JH, et al
    Randomized, multicenter, phase III study of accelerated fraction radiotherapy with concomitant boost to the gross tumor volume compared with conventional fractionation in concurrent chemoradiation in patients with unresectable stage III non-small cell
    Int J Radiat Oncol Biol Phys. 2022 Oct 21. pii: S0360-3016(22)03440.
    PubMed     Abstract available


    September 2022
  80. OWEN D, Siva S, Salama JK, Robinson C, et al
    If at First You Don't Succeed-Stereotactic Body Radiation Therapy for Recurrent Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022;114:5-9.
    PubMed    


    August 2022
  81. HUANG YS, Chen JL, Lan HT, Tai MH, et al
    Xenon-enhanced Ventilation CT for Functional Lung Avoidance Radiotherapy in Patients with Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Aug 24. pii: S0360-3016(22)00754.
    PubMed     Abstract available


  82. WANG S, Mahon R, Weiss E, Jan N, et al
    Automated Lung Cancer Segmentation Using a PET and CT Dual-Modality Deep Learning Neural Network.
    Int J Radiat Oncol Biol Phys. 2022 Aug 4. pii: S0360-3016(22)03067.
    PubMed     Abstract available


  83. YAREMKO BP, Capaldi DPI, Sheikh K, Palma DA, et al
    Functional Lung Avoidance for Individualized Radiation Therapy: Results of a Double-Masked, Randomized Controlled Trial.
    Int J Radiat Oncol Biol Phys. 2022;113:1072-1084.
    PubMed     Abstract available


  84. KOLAHDOUZAN K, Chavoshi M, Bayani R, Darzikolaee NM, et al
    Low-Dose Whole Lung Irradiation for Treatment of COVID-19 Pneumonia: A Systematic Review and Meta-Analysis.
    Int J Radiat Oncol Biol Phys. 2022;113:946-959.
    PubMed     Abstract available


    July 2022
  85. QIU B, Xi Y, Liu F, Li Y, et al
    Gut microbiome is associated with the response to Chemoradiotherapy in Patients with Non-small cell lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jul 26. pii: S0360-3016(22)00749.
    PubMed     Abstract available


  86. XIANG L, Ren PR, Li HX, Ye H, et al
    Effect of three-dimensional interstitial high-dose-rate brachytherapy with regional metastatic lymph node intensity-modulated radiation therapy in locally advanced peripheral non-small cell lung cancer: 5-year follow-up of a phase II clinical trial.
    Int J Radiat Oncol Biol Phys. 2022 Jul 25. pii: S0360-3016(22)00752.
    PubMed     Abstract available


  87. KIM KH, Pyo H, Lee H, Oh D, et al
    Association of T cell senescence with radiation pneumonitis in patients with non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jul 24. pii: S0360-3016(22)00737.
    PubMed     Abstract available


  88. KUMAR S, Wang X, Pittell H, Calip GS, et al
    Real world use of radiation for newly diagnosed brain metastases in ALK-positive lung cancer receiving a first line ALK inhibitor.
    Int J Radiat Oncol Biol Phys. 2022 Jul 20. pii: S0360-3016(22)00730.
    PubMed     Abstract available


  89. LIU F, Qiu B, Xi Y, Luo Y, et al
    Efficacy of thymosin alpha1 in management of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043).
    Int J Radiat Oncol Biol Phys. 2022 Jul 20. pii: S0360-3016(22)00728.
    PubMed     Abstract available


  90. BROWNSTEIN J, Salama JK
    Moderately Hypofractionated Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: A New Way Forward for Dose Escalation?
    Int J Radiat Oncol Biol Phys. 2022;113:749-751.
    PubMed    


    June 2022
  91. CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
    Tumor-derived C-C motif ligand 2 (CCL2) induces the recruitment and polarization of tumor-associated macrophages and increases the metastatic potential of bladder cancer cells in the postirradiated microenvironment.
    Int J Radiat Oncol Biol Phys. 2022 Jun 9. pii: S0360-3016(22)00598.
    PubMed     Abstract available


  92. VICENTE EM, Modiri A, Kipritidis J, Yu KC, et al
    Combining Serial and Parallel Functionality in Functional Lung Avoidance Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2022;113:456-468.
    PubMed     Abstract available


  93. JAGSI R, Schipper M, Mietzel M, Pandya R, et al
    The Michigan Radiation Oncology Quality Consortium: A Novel Initiative to Improve the Quality of Radiation Oncology Care.
    Int J Radiat Oncol Biol Phys. 2022;113:257-265.
    PubMed     Abstract available


    May 2022
  94. NO HJ, Raja N, Von Eyben R, Das M, et al
    Characterization of Metastatic Non-Small Cell Lung Cancer and Oligometastatic Incidence in an Era of Changing Treatment Paradigms.
    Int J Radiat Oncol Biol Phys. 2022 May 30. pii: S0360-3016(22)00476.
    PubMed     Abstract available


  95. CHICAS-SETT R, Zafra J, Rodriguez-Abreu D, Castilla-Martinez J, et al
    Combination of Stereotactic Ablative Radiotherapy With Anti-PD-1 in Oligoprogressive Non-Small-Cell Lung Cancer And Melanoma: Results of a Prospective Multicenter Observational Study.
    Int J Radiat Oncol Biol Phys. 2022 May 17. pii: S0360-3016(22)00421.
    PubMed     Abstract available


    April 2022
  96. BRYANT AK, Sankar K, Strohbehn GW, Zhao L, et al
    Prognostic and Predictive Role of PD-L1 Expression in Stage III Non-small Cell Lung Cancer Treated With Definitive Chemoradiation and Adjuvant Durvalumab.
    Int J Radiat Oncol Biol Phys. 2022 Apr 18. pii: S0360-3016(22)00248.
    PubMed     Abstract available


  97. ROBINSON C, Kruser TJ, Owen D, Salama J, et al
    Fast and Furious: New Data Examining Accelerated Radiation Therapy for Limited-Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022;112:1067-1070.
    PubMed    


  98. SODJI QH, Ko R, von Eyben R, Owen SG, et al
    Acute and Late Esophageal Toxicity After SABR to Thoracic Tumors Near or Abutting the Esophagus.
    Int J Radiat Oncol Biol Phys. 2022;112:1144-1153.
    PubMed     Abstract available


  99. CHEN G, Kong P, Yang M, Hu W, et al
    Golgi Phosphoprotein 3 Confers Radioresistance via Stabilizing EGFR in Lung Adenocarcinoma.
    Int J Radiat Oncol Biol Phys. 2022;112:1216-1228.
    PubMed     Abstract available


    March 2022
  100. SPERDUTO PW, De B, Li J, Carpenter D, et al
    The Graded Prognostic Assessment (GPA) for Lung Cancer Patients with Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA including the Effect of Programmed Death Ligand-1 (PD-L1) and Othe
    Int J Radiat Oncol Biol Phys. 2022 Mar 21. pii: S0360-3016(22)00253.
    PubMed     Abstract available


  101. HOPPE BS, Nichols RC, Flampouri S, Pankuch M, et al
    Chemoradiation with Hypofractionated Proton Therapy in Stage II-III Non-Small Cell Lung Cancer: A YYY Phase 1/2 Trial.
    Int J Radiat Oncol Biol Phys. 2022 Mar 16. pii: S0360-3016(22)00238.
    PubMed     Abstract available


  102. JIAO Z, Li H, Xiao Y, Dorsey J, et al
    Integration of Deep Learning Radiomics and Counts of Circulating Tumor Cells Improves Prediction of Outcomes of Early Stage NSCLC Patients Treated With Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2022;112:1045-1054.
    PubMed     Abstract available


  103. VINOGRADSKIY Y, Castillo R, Castillo E, Schubert L, et al
    Results of a Multi-Institutional Phase 2 Clinical Trial for 4DCT-Ventilation Functional Avoidance Thoracic Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2022;112:986-995.
    PubMed     Abstract available


  104. MA L, Sakamoto Y, Ando K, Fujita H, et al
    Th Balance-Related Host Genetic Background Affects the Therapeutic Effects of Combining Carbon-Ion Radiation Therapy With Dendritic Cell Immunotherapy.
    Int J Radiat Oncol Biol Phys. 2022;112:780-789.
    PubMed     Abstract available


    February 2022
  105. WU Y, Verma V, Liang F, Lin Q, et al
    Local consolidative therapy versus systemic therapy alone for metastatic non-small cell lung cancer: a systematic review and meta-analysis.
    Int J Radiat Oncol Biol Phys. 2022 Feb 20. pii: S0360-3016(22)00169.
    PubMed     Abstract available


  106. SHAVERDIAN N, Shepherd AF, Li X, Offin M, et al
    Impact of Tumor Mutational Burden and Gene Alterations Associated with Radiation-Response on Outcomes of Post-Operative Radiation Therapy in Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Feb 11. pii: S0360-3016(22)00160.
    PubMed     Abstract available


  107. ARRIETA O, Hernandez-Pedro N, Maldonado F, Ramos-Ramirez M, et al
    Nitroglycerin plus whole intracranial radiotherapy for brain metastases in non-small cell lung cancer patients: A randomized, open-label, phase II clinical trial.
    Int J Radiat Oncol Biol Phys. 2022 Feb 11. pii: S0360-3016(22)00156.
    PubMed     Abstract available


  108. KIM KH, Pyo H, Oh HLD, Noh JM, et al
    Dynamics of circulating immune cells during chemoradiotherapy in patients with non-small cell lung cancer support earlier administration of anti-PD-1/PD-L1 therapy.
    Int J Radiat Oncol Biol Phys. 2022 Feb 9. pii: S0360-3016(22)00143.
    PubMed     Abstract available


    January 2022
  109. BRYANT AK, Sankar K, Strohbehn GW, Zhao L, et al
    Timing of Adjuvant Durvalumab Initiation Is Not Associated With Outcomes in Stage III Non-small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jan 31. pii: S0360-3016(22)00002.
    PubMed     Abstract available


  110. CONTRERAS J, Srivastava A, Samson P, DeWees T, et al
    Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2022 Jan 21. pii: S0360-3016(22)00022.
    PubMed     Abstract available


    December 2021
  111. WANG Y, Zhang T, Huang Y, Li W, et al
    Real-world Safety and Efficacy of Consolidation Durvalumab after Chemoradiotherapy for Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Int J Radiat Oncol Biol Phys. 2021 Dec 26. pii: S0360-3016(21)03422.
    PubMed     Abstract available


  112. LI L, Tang S, Yin JC, Dong L, et al
    Comprehensive next-generation sequencing reveals novel predictive biomarkers of recurrence and thoracic toxicity risks following chemoradiotherapy in limited stage small-cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2021 Dec 20. pii: S0360-3016(21)03246.
    PubMed     Abstract available


  113. LEE K, Le T, Hau E, Hanna GG, et al
    A systematic review into the radiological features predicting local recurrence after stereotactic ablative body radiotherapy (SABR) in patients with non-small cell lung cancer (NSCLC): Local recurrence features of NSCLC post-SABR.
    Int J Radiat Oncol Biol Phys. 2021 Dec 5. pii: S0360-3016(21)03235.
    PubMed     Abstract available


  114. YE R, Qiao Y, Singh PK, Wang Y, et al
    High-Content Clonogenic Survival Screen to Identify Chemoradiation Sensitizers.
    Int J Radiat Oncol Biol Phys. 2021;111:e27-e37.
    PubMed     Abstract available


    November 2021
  115. UEKI K, Matsuo Y, Takeda A, Morita S, et al
    Impact of local recurrence on cause-specific death after stereotactic body radiotherapy for early-stage non-small cell lung cancer: dynamic prediction using landmark model.
    Int J Radiat Oncol Biol Phys. 2021 Nov 25. pii: S0360-3016(21)03223.
    PubMed     Abstract available


  116. WILKIE JR, Hochstedler KA, Schipper MJ, Matuszak MM, et al
    Association Between Physician and Patient Reported Symptoms in Patients Treated with Definitive Radiotherapy for Locally Advanced Lung Cancer in a Statewide Consortium.
    Int J Radiat Oncol Biol Phys. 2021 Nov 25. pii: S0360-3016(21)03222.
    PubMed     Abstract available


  117. RANKINE LJ, Wang Z, Kelsey CR, Bier E, et al
    Hyperpolarized (129)Xe Magnetic Resonance Imaging for Functional Avoidance Treatment Planning in Thoracic Radiation Therapy: A Comparison of Ventilation- and Gas Exchange-Guided Treatment Plans.
    Int J Radiat Oncol Biol Phys. 2021;111:1044-1057.
    PubMed     Abstract available


  118. BITTERMAN DS, Selesnick P, Bredfeldt J, Williams CL, et al
    Dosimetric Planning Tradeoffs to Reduce Heart Dose Using Machine Learning-Guided Decision Support Software in Patients with Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Nov 11. pii: S0360-3016(21)03117.
    PubMed     Abstract available


  119. WANG R, Wu S, Qian D, Zhang Y, et al
    A Lung Cancer Auxiliary Diagnostic Method: Deep Learning Based Mediastinal Lymphatic Partitions Segmentation for Cancer Staging.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  120. XU R, Zhang B, Tian Y
    MRI-Based Radiomics Signature for the Prediction of Response of Lung Cancer Brain Metastases After Whole-Brain Radio-Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  121. TATINENI V, O'Shea PJ, Rauf Y, Jia X, et al
    Outcomes of BRAF, MET, RET, and ROS1 Mutated Non-Small Cell Lung Cancer With Brain Metastases (NSCLCBM).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  122. TATINENI V, O'Shea PJ, Rauf Y, Jia X, et al
    Outcomes of Immune-Checkpoint Inhibitors (ICIs) and Stereotactic Radiosurgery (SRS) in Non-Small Cell Lung Cancer Brain Metastases (NSCLCBM) Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  123. PORTE J, Martin CS, Moreau TF, Massiani MA, et al
    Loco-Regional Control and Survival Outcomes After Combined Stereotactic Radiation Therapy and Immune Checkpoint Inhibitors for Brain Metastases From Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  124. LIAN Y, Tian Y
    The Clinical Study of the Effect of WBRT on Cognitive Function of Patients With Brain Metastasis of Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  125. KONG C, Zhu X, Jiang M, Song X, et al
    Anlotinib in Combination With Whole Brain Radiotherapy for Advanced Non-Small-Cell Lung Cancer With Brain Metastases Progressive or Developed After at Least One Lines of Prior Treatment.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  126. KONG T, Nichol A, Ho C, Benny A, et al
    Population-Based Analysis of Outcomes for Patients With Brain Metastases From Epidermal Growth Factor Receptor Mutation Positive Non-Small Cell Lung Cancer Treated With Tyrosine Kinase Inhibitor Alone or Combined With Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  127. GUREWITZ J, Patel D, Benjamin C, Donahue BR, et al
    Survival in Patients with >/=5 Brain Metastases From Non-Small Cell Lung Cancer Treated With Upfront Stereotactic Radiosurgery.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  128. DOHM AE, Tang J, Mills MN, Perez BA, et al
    Clinical Outcomes of Non-Small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitors, EGFR Tyrosine Kinase Inhibitors, Chemotherapy and Immune Checkpoint Inhibitors, or Chemotherapy Alone.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  129. IYENGAR P, Allen BG, Kelsey CR, Holmlund J, et al
    GRECO-1: Phase 1/2 Study of Stereotactic Body Radiation Therapy (SBRT) With or Without GC4711 for Early Stage, Centrally Located or Large Non-Small Cell Lung Cancer (NSCLC).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  130. HIGGINS KA, Hu C, Stinchcombe TE, Jabbour SK, et al
    NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  131. ZHAO L, Zhou W, Yin Y, Shi M, et al
    Hypofractionated vs. Twice Daily Radiotherapy for Limited Stage Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  132. YAN M, Sigurdson S, Greifer N, Kennedy T, et al
    A Comparison of Hypofractionated and Twice Daily Thoracic Irradiation in Limited-Stage Small Cell Lung Cancer: An Overlap Weighted Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  133. XINGWEN F, Pan L, Wang Y, Ye S, et al
    Limited Stage Small Cell Lung Cancer Patients With Complete Response After Thoracic Chemoradiotherapy Still Benefit From Prophylactic Cranial Irradiation in the MRI Era.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  134. RIMNER A, Lai V, Califano R, Jabbour SK, et al
    Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Limited-Stage Small-Cell Lung Cancer: KEYLYNK-013.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  135. LUO J, Xu C, Song J, Xiao L, et al
    Simultaneous Integrated Dose Reduction Intensity-Modulated Radiotherapy Effectively Reduces Cardiac Irradiation Dose in Limited-Stage Small-Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  136. SUN H, Huang W, Li B
    Twice-Daily Thoracic Radiotherapy by Intensity-Modulated Radiation Therapy (IMRT) or Simultaneous Integrated Boost (SIB) IMRT With Concurrent Chemotherapy for Limited-Stage Small Cell Lung Cancer Patients? A Propensity-Score Matched Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  137. MAJEED S, Aparnathi M, Song L, Weiss J, et al
    The First-in-Class UBA1 Inhibitor, TAK-243, in Combination With Radiotherapy for YAP1 and BEND3 Biomarker-Defined Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  138. KELLER A, Kim H, Beriwal S, Smith KJ, et al
    Cost-Effectiveness of Prophylactic Cranial Irradiation vs. MRI Surveillance for Extensive Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  139. GROSS AJ, Kharouta MZ, Podder TK, Choi S, et al
    Role of Thoracic Radiotherapy in Extensive Stage Small Cell Lung Cancer (ES-SCLC) in the Immunotherapy Era: A National Hospital-Based Registry Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  140. FAN X, Li B, Wang S, Fan B, et al
    Prophylactic Cranial Irradiation-Related Lymphopenia Affects Progression-Free Survival in Patients With Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  141. BILLING D, Rimner A, Shepherd AF, Gelblum D, et al
    Standard vs. Higher-Dose Consolidative Thoracic Radiation in Extensive-Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  142. LESTER-COLL NH, Skelly J, Vacek PM, Sprague BL, et al
    Trends and Costs of Stereotactic Body Radiation Therapy in Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  143. ZHU F, Wang H, Ashamalla H
    Role of Adjuvant Radiation in pN1 Non-Small Cell Lung Cancer (NSCLC) Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  144. ZHOU Y, Batus M, Fidler M, Bonomi P, et al
    Adrenal Stereotactic Body Radiation Therapy in the Management of Oligometastatic Lung Cancer: Patient Selection Matters.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  145. ZHU F, Wang H, Ashamalla H
    Role of Adjuvant Radiation in pN2 Non-Small Cell Lung Cancer (NSCLC) Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  146. ZHAO Q, Wang L
    Clinical Parameters Combined With Radiomics Features to Predict the Efficacy of Immunotherapy for Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  147. YUAN M, Zhai YR, Men Y, Hui Z, et al
    Endostar (Rh-Endostatin) Enhanced the (Chemo)Radiosensitivity in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  148. YANG W, Su SF, Ouyang W, Ma Z, et al
    To Evaluate the Efficiency and Safety of Nab-paclitaxel Plus Cisplatin and Concomitant Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  149. YANG G, Li B, Liu C
    A Prospective Phase II Clinical Study of Simultaneous Integrated Boost Radiotherapy on Stage III Local-advanced Non-Small Cell Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  150. YANG L, Li B, Xu Y, Zou B, et al
    The Role of Adjuvant Chemotherapy in Patients With Stage IB Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  151. XIANG L, Wu JB
    The 3-Year Outcome of 3D High-Dose-Rate Brachytherapy in Combination With Regional Metastatic Lymph Nodes Intensity-Modulated Radiotherapy in Peripheral Locally Advanced Non-Small Cell Lung Cancer: A Phase I/II Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  152. WU L, Bi N, Wang L
    Efficacy and Safety of Thoracic Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer Patients With Pre-Existing Interstitial Lung Diseases: A Single Center Experience of 85 Cases.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  153. WEISS E, Ricco A, Mukhopadhyay ND, Gharai LR, et al
    Predictors of High-Grade Radiation Pneumonitis and Overall Survival Following Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Analysis of Lung and Heart Dose Parameters and the Impact of Treatment Technique.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  154. WESTERGAARD SA, Castillo R, Rupji M, Bell J, et al
    Sparing Functional Lung Using Optimized Volumetric Modulated Arc Therapy in Thoracic Radiation for Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  155. HALL MD, Tom MC, Kotecha R, Von Werne K, et al
    Patterns of Care in Stereotactic Body Radiation Therapy Fractionation Schedules in Non-Small Cell Lung Cancer in the United States From 2004-2016.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  156. TENG F, Wang P
    Anti-PD-1 With or Without Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  157. WANG F, D'Rummo KA, Cao Y, Huang CH, et al
    Real-World Data for Integration Strategy of Radiotherapy (RT) With Immunotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  158. TANAKA H, Ono T, Takano H, Manabe Y, et al
    Monocyte-to-Lymphocyte Ratio is a Significant Prognostic Factor for Patients With Non-Small Cell Lung Cancer Who Treated By Stereotactic Body Radiation Therapy: A Multi Institutional Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  159. TOMITA N, Okuda K, Hashimoto S, Murai T, et al
    Role of Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer in Borderline Patients for Surgery due to Impaired Pulmonary Function.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  160. SUN X, Men Y, Yang X, Deng L, et al
    Recurrence Dynamics After Complete Resection and Adjuvant Chemotherapy in Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  161. SUN S, Men Y, Yang X, Sun X, et al
    Risk Factors of Brain Metastases in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  162. SMITH DR, Riportella M, Shepherd AF, Guttmann DM, et al
    Safety and Effectiveness of Definitive Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer Among Older Patients: Does Frailty Matter?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  163. SHEPHERD AF, Yu A, Margaret CA, Rhyne RF, et al
    The Correlation Between Changes in Cardiac Biomarkers and Cardiac Events in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Stereotactic Body Radiation Therapy (SBRT) - Exploratory Analysis of a Phase II Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  164. RICHMAN AH, Patel AK, Beriwal S, Wilhite TJ, et al
    Primary Tumor Control in Stereotactic Ablative Radiation Therapy for Large (>/= 5 cm) Non-Small Cell Lung Cancer: Does It Last?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  165. QIAO EM, Voora RS, Nalawade V, Kotha NV, et al
    Evaluating Clinical Trends and Benefits of Low-Dose CT in Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  166. PENNOCK MM, Halmos B, Iii WRB, Cheng H, et al
    Predictors of Early Durvalumab Discontinuation After Chemoradiotherapy for Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  167. MARAR M, Bryant AK, Nalawade V, Das M, et al
    Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  168. MAINA P, Garg MK, Kalnicki S, Ohri N, et al
    Predictors of Missed On-Treatment Visits During Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  169. MARKAN K, Saeed A, Hamza MA, Vyfhuis MAL, et al
    Lymphopenia Assessment in Stage III Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With Proton or Photon Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  170. SU SF, Liu FL, Li Q, Hu Y, et al
    Metastatic Non-Small Cell Lung Cancer Treated With Chemotherapy Combined With Concurrent Radiation Therapy to the Primary Tumor: Characterization of Long-term Survivor and Prognostic Value of Lung Immune Prognostic Index in Two Prospective Studies.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  171. LIU H, Qiu B, Wang D, Zhang X, et al
    Dynamic 18F-FDG Total Body PET Imaging as a Predictive Marker of Induction Chemo-Immunotherapy Followed by Concurrent Chemoradiotherapy Response in Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  172. LIU KX, Sierra-Davidson K, Tyan K, Orlina LT, et al
    Clinical Outcomes After Trimodality Therapy With Dose-Escalated Neoadjuvant Intensity-Modulated Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  173. CHEN N, Li Q, Wang S, Xiong M, et al
    Hypo-Fractionated Radiotherapy With Concurrent Chemotherapy (HFRT-CHT) for Locoregional Recurrence of Non-Small Cell Lung Cancer After Complete Resection: A Prospective, Single-Arm, Phase II Study (GASTO1017).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  174. LARREA L, Gonzalez V, Antonini P, Lopez E, et al
    Lattice Radiotherapy (LRT)-Spatially Fractionated Radiotherapy (SFRT): Advanced Non-Small Cell Lung Cancer (NSCLC): Early Experience.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  175. KOFFER PP, Belani N, DiPetrillo TA, Hepel JT, et al
    Risk of Pneumonitis in Patients With Stage III Non-Small Cell Lung Cancer Treated With Definitive Chemo-RT and Durvalumab Consolidation.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  176. KANG BH, Lee JH, Xue L, Son J, et al
    Prediction of Delayed Lymphopenia at the Time of Consolidation Immunotherapy After Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  177. JABBOUR SK, Cho BC, Bria E, Kato T, et al
    KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III NonSmall-Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  178. IMANO N, Kimura T, Kawahara D, Kubo K, et al
    Potential Benefits of Volumetric Modulated Arc Therapy to Reduce the Incidence of Grade 2 Radiation Pneumonitis in Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  179. HU HP, Walker C, Swaminath A
    Real-World Outcomes of Chemoradiation and Consolidative Durvalumab in Unresectable Stage III Non-Small-Cell Lung Cancer - A Systematic Review.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  180. HILL C, Fu W, Hu C, Chen X, et al
    Investigating Patient-Reported Outcomes as a Tool for Assessing Risk of Developing Radiation Pneumonitis After Thoracic Radiation in Patients With Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  181. HE K, Zhang S, Pang J, Yin J, et al
    Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Toxicity and Efficacy in Non-Small-Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  182. HE K, Barsoumian HB, Yang L, Hu Y, et al
    Selective Inhibition of STAT6 With Antisense Nucleotides Enhances Systemic Antitumor Effect of Hypofractionated Radiotherapy and Anti-PD1 in Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  183. DIAMOND BH, Shukla U, Andrea S, DiPetrillo TA, et al
    Chemoradiation vs. Radiation Alone in the Management of Inoperable cT1-T2N1 Non-Small Cell Lung Cancer, a Propensity-Weighted Hospital Database Analysis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  184. DEVINE M, Merriott DJ, Say C, Yoo C, et al
    Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  185. DE LEO AN, Braschi EL, Morris CG, Yeung AR, et al
    No Difference in Outcomes for Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Pathologic Diagnosis.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  186. CORDOVA JS, Brenneman RJ, Kang KH, Vlacich GR, et al
    Impact of ITV/GTV Ratio on Local Failure in Early Stage Non-Small Cell Lung Cancer Patients Receiving Stereotactic Ablative Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  187. COPELLA A, Deng M, Handorf E, Kumar SS, et al
    Effect of Adjuvant Chemotherapy After SBRT for Node Negative, Non-Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  188. CHAUDHARY KR, Halmos B, Cheng H, Cheng SK, et al
    Bmi1 Resistance Pathway and Immune Checkpoint Blockade in Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  189. BOWES C, Durgin B, Thomas S, Keane FK, et al
    Esophagitis Outcomes With or Without Contralateral Esophagus Sparing in Locally Advanced Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  190. BURBURE N, Deng M, Handorf E, Kumar SS, et al
    Clinical Significance of Total Radiation Dose for Patients With Treatment Delays in Stage III Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  191. ATKINS KM, Bitterman DS, Nohria A, Aerts H, et al
    Critical Volumetric Threshold of 15 Gy Exposure to Left Coronary Arteries Predicts Major Adverse Cardiac Events and Mortality in Lung Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  192. ARBAB M, Ellsworth SG, Huang K, Edwards DM, et al
    The Association Between Radiation to the Immune System and Overall Survival and Disease Progression in Non-Small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  193. APPEL S, Lawrence Y, Goldstein JD, Bar J, et al
    Are Advanced Radiation Techniques Safe to Use in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)? Analysis Based on Pathologic Regression and Local Recurrence.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  194. ANDRAOS TY, Shirvani S, Cornwell T, Ohri N, et al
    Characterization of the Entire Metastatic Spectrum for Non-Small Cell Lung Cancer in the Immunotherapy Era.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  195. DU D, Abuali T, Ladbury CJ, Liu JR, et al
    Biologically Active Volume of Disease (BaVD) Predicts for Survival in Metastatic Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  196. AGABALOGUN T, Heiden B, Spraker MB, Badiyan SN, et al
    Post-Operative Radiation Therapy for Non-Small Cell Lung Cancer Patients With Higher Positive to Examined Lymph Node Ratio is Associated With Improved Overall Survival.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  197. YANG L, Xu ZYZ, Zhang F, Jin JY, et al
    Predicting Changes in Circulating Immune Cells During Thoracic Radiation in Patients With Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  198. CHEN Y, Yu J, Meng X
    Safety of Thoracic Radiotherapy After PD-(L)1 Inhibitor Treatment in Patients With Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  199. NI J, Wu L, Ai X, Dong X, et al
    XX (a PD-1 Inhibitor), Stereotactic Body Radiotherapy and Granulocyte-Macrophage Colony Stimulating Factor as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer: Safety Run-In Results of a Prospective, Multicenter, Phase II Trial.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  200. BOURBONNE V, Jaouen V, Hatt M, Pradier O, et al
    Development and Validation of a Spatial Dose Pattern Based Model Predicting Acute Pulmonary Toxicity in Patients Treated With Volumetric Arc-Therapy for Locally Advanced Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  201. MONTOYA C, Spieler B, Welford SM, Dal Pra A, et al
    Predicting Response to Immunotherapy in Non-Small Cell Lung Cancer - From Bench to Bedside.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  202. ALL S, Iyengar P, Westover KD, Choy H, et al
    Patterns of Failure in Metastatic Non-Small Cell Lung Cancer Patients After Initiation of Pembrolizumab.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  203. ABANA CO, Hu Y, Paris S, Barsoumian HB, et al
    NBTXR3 Nanoparticle With Immunoradiation Might Reshape Metastatic Tumor-Infiltrating T Cell Repertoire in Murine Lung Cancer Model.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  204. LESTER-COLL NH, Anker CJ, Atherly A, Sprague BL, et al
    Cost-Effectiveness of Intensity Modulated Radiation Therapy vs. 3D Conformal Radiation Therapy in Stage III Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  205. SAEED NA, Lee Y, Park HSM
    Multi-Facility vs. Single-Facility Concurrent Chemoradiation for Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  206. MCGUNIGAL M, Singh T, Amarell K, Aghdam N, et al
    Association Between Travel Distance and Use of Postoperative Radiation Therapy for Incompletely Resected Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  207. MCGUNIGAL M, Amarell K, Singh T, Chou J, et al
    Predictors and Consequences of Refusing Recommended Radiation for Locally Advanced Inoperable Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  208. KANG KH, Brenneman RJ, Waters MR, Cordova JS, et al
    The Influence of Neighborhood Socioeconomic Status and Follow-up on Survival in Early-Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  209. MO A, Guha C, Guha U, Ohri N, et al
    High Tumor Mutational Burden in Rare and Complex EGFR Mutant Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  210. TANG J, Gong Y
    Synergistic Effect of Phloretin Combined With Radiotherapy on Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  211. SON C, Moey M, Naqash A, Walker P, et al
    Cardiotoxicity in Patients With Lung Cancer Receiving Thoracic Radiotherapy and Immune-Checkpoint Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  212. CHEN W, Yang L, Xu W, Liang Z, et al
    IDO Immune Status After Radiotherapy in Patients With IV Stage Non-Small Cell Lung Cancer: An Exploratory Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  213. TJONG MC, Doherty M, Tan H, Chan WC, et al
    Analysis of Patient Reported Outcomes for Stage IV Non-Small Cell Lung Cancer Patients in Ontario.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  214. LI ZH, Giuliani ME, Ingledew PA
    Characteristics Assessment of Online YouTube Videos on Radiotherapy for Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  215. RACHI T, Tanaka Y, Togo H, Raturi VP, et al
    Examination of Conversion Method of Dose Distribution of Lung Cancer IMRT Using Fluence Reversible Calculation Function in O-Ring Type Linac and C Type Linac.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  216. PELES O, Atya HB, Shamir R, Berger B, et al
    Segmentation of the Upper Torso for Lung Cancer TTFields Treatment Planning.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  217. COHEN JD, Sanchez-Cerro MK, Vyfhuis MAL, Patel AN, et al
    Role of Modified Frailty Index in Predicting Oncologic Outcomes From Moderately Hypofractionated Radiotherapy for Patients with Stage I-IIB Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  218. NENOFF L, Kothe A, Matter M, Amaya E, et al
    TCP and NTCP Calculations Based on Treatment Doses Instead of Planned Doses for Daily Adaptive Proton Therapy of Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  219. KIM Y, Saraf A, Iii DMM, Gainor J, et al
    Quantitative Evaluation of Normal Lung Density Changes in Non-Small Cell Lung Cancer Patients Treated With Radiotherapy and PD-1 Immune Checkpoint Inhibitors.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  220. USUI K, Ogawa K, Goto M, Sakano Y, et al
    Cycle-Generative Adversarial Network-Based Image Correction of 4-Dimensional Cone-Beam Computed Tomography for Lung Cancer Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  221. NOID G, Tai A, Zhong H, Shah J, et al
    Lung Perfused Blood Volume Calculated From Dynamic Contrast Enhanced DECT for Radiation Treatment Planning of Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  222. ZHANG Z, Lee SH, Caruana R, Fan Y, et al
    Circulating Tumor Cell Assay Enables Prediction of Recurrence Following Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: An Interpretable Machine Learning Study.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  223. YAN M, Zhang Z, Wang R, Yu J, et al
    Predicting Response of Lung Cancer with Definitive Radiation Therapy: A Radiomics-Based Prediction Model.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  224. NESS E, Wagstaff P, Kaur M, Harris AA, et al
    Machine Learning Classifier Using Pretreatment Factors to Predict Radiation Pneumonitis Following Stereotactic Body Radiation Therapy for Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  225. CHEN N, Qiu B, Zhou Y, Luo Y, et al
    Radiomic Features of Tumor and Tumor Organismal Environment in Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Retrospective Analysis of Survival Prediction.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  226. MA Z, Yongxing B, Yuan M, Yang X, et al
    Development and Validation of Deep Learning Model Based on CT Simulator Images to Predict 5-Year Recurrence of Stage IIIA-N2 Non-Small-Cell Lung Cancer Patients Treated with Surgery and Postoperative Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  227. GAINEY JC, He Y, Zhu R, Kim Y, et al
    The Predictive Power of a Deep-Learning Segmentation Based Prognostication (DESEP) Model in Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  228. QIN A, Liu G, Chen S, Zhao L, et al
    Investigate the Feasibility of Using CBCT to Assess the Dose Validation for Spot-Scanning Proton Arc (SPArc) Therapy for Advanced Staged Lung Cancer Treatment.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  229. YANG Y, Bi N, Zhang T, Wang L, et al
    Circulating Tumor DNA Dynamics Predict Prognosis of Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Definitive Chemoradiotherapy.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  230. WILLIAMS TM, Welliver MX, Brownstein JM, Otterson G, et al
    A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  231. BOGART JA, Wang X, Masters G, Gao J, et al
    Mature Outcomes of 61.2 Gy Concomitant Boost (CB) Thoracic Radiotherapy (TRT) in Limited Stage Small Cell Lung Cancer (LSCLC): CALGB 30610 (Alliance) / RTOG 0538.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  232. HOSNY A, Bitterman DS, Guthier CV, Roberts H, et al
    Clinical Validation of Deep Learning Algorithms for Lung Cancer Radiotherapy Targeting.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  233. VICENTE EM, Modiri A, Kipritidis J, Hagan A, et al
    Accounting for Serial and Parallel Functionality of the Lung May Minimize Post-Radiotherapy Loss of Respiratory Function in Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  234. MANNING M, Yongue C, Garikipati A, Cykert S, et al
    Overall Survival From a Prospective Multi-Institutional Trial to Resolve Black-White Disparities in the Treatment of Early Stage Breast and Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  235. FORGHANI F, Castillo R, Castillo E, Jones BL, et al
    Is Perfusion Dose-Response Different Than Ventilation Dose-Response for Lung Cancer Patients Treated With Radiotherapy?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  236. BENKHALED S, Koshariuk O, Van Esch A, Remouchamps VM, et al
    Dosimetric Impact of Intrafraction Motion During Peripheral Lung Cancer Stereotactic Radiotherapy: Is a Second Cone Beam Computed Tomography of Added Value?
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  237. RYDZEWSKI NR, Buehler D, Kendziorski C, Iyer G, et al
    Immune-Depleted Phenotype in Non-Small Cell Lung Cancer Brain Metastases Predicts for Worse Overall Survival.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  238. HERR DJ, Hochstedler K, Yin H, Dess RT, et al
    Effect of Education and Standardization of Cardiac Dose Constraints on Heart Dose in Lung Cancer Patients Receiving Definitive Radiation Therapy Across a Statewide Consortium.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  239. TJONG MC, Bitterman DS, Brantley KD, Nohria A, et al
    Cardiac Radiation Dose and Patient Risk Factors for Predicting Major Adverse Cardiac Events in Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  240. XI Y, Qiu B, Li Y, Xie X, et al
    Diagnostic Signatures for Lung Cancer by Gut Microbiome and Urine Metabolomics Profiling.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  241. YANG DX, Khera R, Chang E, Joel M, et al
    Comparison of Machine Learning Approaches for Missing Data Imputation Among Non-Small Cell Lung Cancer Patients.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  242. THOR M, Shepherd AF, Apte A, Offin M, et al
    Pre-Treatment Immune-Related Markers Predict Disease Outcomes in Non-Small Cell Lung Cancer Patients Treated With Chemoradiation and Durvalumab.
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  243. MITCHELL P, O'Byrne KJ, Brown C, Jurkovic H, et al
    A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD).
    Int J Radiat Oncol Biol Phys. 2021;111.
    PubMed     Abstract available


  244. HU Y, Paris S, Barsoumian H, Abana CO, et al
    Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects.
    Int J Radiat Oncol Biol Phys. 2021;111:647-657.
    PubMed     Abstract available


    October 2021
  245. KOWALCHUK RO, Niranjan A, Lee CC, Yang HC, et al
    yReirradiation with stereotactic radiosurgery after local or marginal recurrence of brain metastases from previous radiosurgery.
    Int J Radiat Oncol Biol Phys. 2021 Oct 10. pii: S0360-3016(21)02904.
    PubMed     Abstract available


  246. AL-RASHDAN A
    In Regard to Small et al.
    Int J Radiat Oncol Biol Phys. 2021;111:577-578.
    PubMed    


    September 2021
  247. AMINI A, Verma V, Simone CB 2nd, Chetty IJ, et al
    American Radium Society Appropriate Use Criteria on Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Sep 24. pii: S0360-3016(21)02823.
    PubMed     Abstract available


  248. ZHU X, Wang Y, Jiang C, Li X, et al
    Radiosensitivity-specific proteomic and signaling pathway network of non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2021 Sep 7. pii: S0360-3016(21)02776.
    PubMed     Abstract available


  249. REIJMEN E, De Mey S, De Mey W, Gevaert T, et al
    Fractionated Radiation Severely Reduces the Number of CD8+ T Cells and Mature Antigen Presenting Cells Within Lung Tumors.
    Int J Radiat Oncol Biol Phys. 2021;111:272-283.
    PubMed     Abstract available


    August 2021
  250. WANG K, Malkin HE, Patchett ND, Pearlstein KA, et al
    Coronary Artery Calcifications and Cardiac Risk after Radiotherapy for Stage III Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Aug 19. pii: S0360-3016(21)02705.
    PubMed     Abstract available


  251. MEI T, Yang X, Yu Y, Tian X, et al
    Secondary infections after diagnosis of severe radiation pneumonitis (SRP) among non-small cell lung cancer patients: pathogen distributions, choice of empirical antibiotics and the value of empirical antifungal treatment.
    Int J Radiat Oncol Biol Phys. 2021 Aug 18. pii: S0360-3016(21)02710.
    PubMed     Abstract available


  252. TRAPPETTI V, Fernandez-Palomo C, Smyth L, Klein M, et al
    Synchrotron Microbeam Radiotherapy for the treatment of lung carcinoma: a pre-clinical study.
    Int J Radiat Oncol Biol Phys. 2021 Aug 5. pii: S0360-3016(21)02630.
    PubMed     Abstract available


  253. JACOBSON G, Lawrence YR, Appel S, Weiss I, et al
    Benefits of Continuous Positive Airway Pressure (CPAP) During Radiation Therapy: A Prospective Trial.
    Int J Radiat Oncol Biol Phys. 2021;110:1466-1472.
    PubMed     Abstract available


  254. NAZ S, Leiker AJ, Choudhuri R, Preston O, et al
    Pharmacological Inhibition of HSP90 Radiosensitizes Head and Neck Squamous Cell Carcinoma Xenograft by Inhibition of DNA Damage Repair, Nucleotide Metabolism, and Radiation-Induced Tumor Vasculogenesis.
    Int J Radiat Oncol Biol Phys. 2021;110:1295-1305.
    PubMed     Abstract available


  255. PRASANNA PG, Rawojc K, Guha C, Buchsbaum JC, et al
    Normal Tissue Injury Induced by Photon and Proton Therapies: Gaps and Opportunities.
    Int J Radiat Oncol Biol Phys. 2021;110:1325-1340.
    PubMed     Abstract available


    July 2021
  256. MCFARLANE MR, Hochstedler KA, Laucis AM, Sun Y, et al
    Predictors of Pneumonitis after Conventionally Fractionated Radiotherapy for Locally Advanced Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Jul 24. pii: S0360-3016(21)02561.
    PubMed     Abstract available


  257. XU T, Meng QH, Gilchrist SC, Lin SH, et al
    Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiotherapy-Induced Cardiotoxicity in Non-Small Cell Lung Cancer Patients: A Secondary Analysis of a Prospective Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2021 Jul 21. pii: S0360-3016(21)00905.
    PubMed     Abstract available


  258. SOYFER V, Gutfeld O, Shamai S, Schlocker A, et al
    COVID-19 Vaccine-Induced Radiation Recall Phenomenon.
    Int J Radiat Oncol Biol Phys. 2021;110:957-961.
    PubMed     Abstract available


  259. JIANG W, Song Y, Sun Z, Qiu J, et al
    Dosimetric Factors and Radiomics Features Within Different Regions of Interest in Planning CT Images for Improving the Prediction of Radiation Pneumonitis.
    Int J Radiat Oncol Biol Phys. 2021;110:1161-1170.
    PubMed     Abstract available


  260. QIU B, Wang D, Li Q, Wu Y, et al
    Concurrent chemoradiotherapy with or without nimotuzumab in locally advanced squamous cell lung cancer: a phase 2 randomized trial.
    Int J Radiat Oncol Biol Phys. 2021 Jul 3. pii: S0360-3016(21)00824.
    PubMed     Abstract available


  261. ALAM SR, Zhang P, Zhang SY, Chen I, et al
    Early Prediction of Acute Esophagitis for Adaptive Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;110:883-892.
    PubMed     Abstract available


    June 2021
  262. TSAO MN, Louie AV
    Radical Radiation for Large-Volume Locally Advanced Non-Small Cell Lung Cancer: Constrained by Constraints!
    Int J Radiat Oncol Biol Phys. 2021;110:261-263.
    PubMed    


  263. KRUSER TJ, Robinson C, Owen D, Salama JK, et al
    Strike or Spare? A Review of Lung-Sparing Therapies for Malignant Pleural Mesothelioma.
    Int J Radiat Oncol Biol Phys. 2021;110:257-260.
    PubMed    


  264. PARHAR R, Livergant J, Lefresne S
    Review of Palliative Radiation Therapy Patterns of Practice for Adrenal Metastases in British Columbia.
    Int J Radiat Oncol Biol Phys. 2021;110:438-443.
    PubMed     Abstract available


  265. CHUNG EJ, Kwon S, Reedy JL, White AO, et al
    IGF-1 Receptor Signaling Regulates Type II Pneumocyte Senescence and Resulting Macrophage Polarization in Lung Fibrosis.
    Int J Radiat Oncol Biol Phys. 2021;110:526-538.
    PubMed     Abstract available


  266. SCHULTKE E, Bayat S, Bartzsch S, Brauer-Krisch E, et al
    A Mouse Model for Microbeam Radiation Therapy of the Lung.
    Int J Radiat Oncol Biol Phys. 2021;110:521-525.
    PubMed     Abstract available


  267. LIU HC, Viswanath DI, Pesaresi F, Xu Y, et al
    Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
    Int J Radiat Oncol Biol Phys. 2021;110:492-506.
    PubMed     Abstract available


    May 2021
  268. YU F, Ni J, Zeng W, Zhou Y, et al
    Clinical value of upfront cranial radiotherapy in osimertinib-treated EGFR-mutant non-small-cell lung cancer with brain metastases.
    Int J Radiat Oncol Biol Phys. 2021 May 28. pii: S0360-3016(21)00667.
    PubMed     Abstract available


  269. VIDETIC GMM, Reddy CA, Woody NM, Stephans KL, et al
    Ten-Year Experience in Implementing Single-Fraction Lung SBRT for Medically Inoperable Early Stage Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 May 25. pii: S0360-3016(21)00658.
    PubMed     Abstract available


  270. QIU B, Li Q, Liu J, Huang Y, et al
    Moderately Hypofractionated Once-daily Compared with Twice-daily Thoracic Radiotherapy Concurrently with Etoposide and Cisplatin in Limited-stage Small-cell Lung Cancer: a Multi-center, Phase II, Randomized Trial.
    Int J Radiat Oncol Biol Phys. 2021 May 13. pii: S0360-3016(21)00490.
    PubMed     Abstract available


  271. KIM H, Keller A, Beriwal S, Smith KJ, et al
    Cost-Effectiveness of Prophylactic Cranial Irradiation versus MRI Surveillance for Extensive Stage Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 May 10. pii: S0360-3016(21)00477.
    PubMed     Abstract available


  272. LEE P, Loo BW Jr, Biswas T, Ding GX, et al
    Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021;110:160-171.
    PubMed     Abstract available


  273. KONG FS, Moiseenko V, Zhao J, Milano MT, et al
    Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?
    Int J Radiat Oncol Biol Phys. 2021;110:172-187.
    PubMed     Abstract available


    April 2021
  274. STEBER CR, Hughes RT, Urbanic J, Clark H, et al
    Long-Term Outcomes from a Phase 2 Trial of Radiofrequency Ablation Combined with External Beam Radiation Therapy for Patients with Inoperable Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2021 Apr 28. pii: S0360-3016(21)00402.
    PubMed     Abstract available


  275. SHURYAK I, Kachnic LA, Brenner DJ
    Lung Cancer and Heart Disease Risks Associated with Low-Dose Pulmonary Radiotherapy to COVID-19 Patients with Different Background Risks.
    Int J Radiat Oncol Biol Phys. 2021 Apr 27. pii: S0360-3016(21)00379.
    PubMed     Abstract available


  276. MALDONADO F, Gonzalez-Ling A, Onate-Ocana LF, Cabrera-Miranda LA, et al
    Prophylactic Cranial Irradiation in high-risk metastatic non-small cell lung cancer patients: Quality of life and neurocognitive analysis of a randomized phase II study.
    Int J Radiat Oncol Biol Phys. 2021 Apr 26. pii: S0360-3016(21)00378.
    PubMed     Abstract available


  277. TATEISHI Y, Takeda A, Horita N, Tsurugai Y, et al
    Stereotactic body radiotherapy with a high maximum dose improves local control, cancer-specific death and overall survival in peripheral early-stage non-small cell lung cancer.
    Int J Radiat Oncol Biol Phys. 2021 Apr 20. pii: S0360-3016(21)00375.
    PubMed     Abstract available


  278. MENDEZ ROMERO A, Schillemans W, van Os R, Koppe F, et al
    The Dutch-Belgian Registry of Stereotactic Body Radiation Therapy for Liver Metastases: Clinical Outcomes of 515 Patients and 668 Metastases.
    Int J Radiat Oncol Biol Phys. 2021;109:1377-1386.
    PubMed     Abstract available


  279. VAN LIMBERGEN EJ, Hoeben A, Lieverse RIY, Houben R, et al
    Toxicity of L19-Interleukin 2 Combined with Stereotactic Body Radiation Therapy: A Phase 1 Study.
    Int J Radiat Oncol Biol Phys. 2021;109:1421-1430.
    PubMed     Abstract available


  280. TROVO M, Relevant A, Polesel J, Muraro E, et al
    Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2021;109:1368-1376.
    PubMed     Abstract available


  281. HASLETT K, Bayman N, Franks K, Groom N, et al
    Isotoxic Intensity Modulated Radiation Therapy in Stage III Non-Small Cell Lung Cancer: A Feasibility Study.
    Int J Radiat Oncol Biol Phys. 2021;109:1341-1348.
    PubMed     Abstract available


  282. THOR M, Apte A, Haq R, Iyer A, et al
    Using Auto-Segmentation to Reduce Contouring and Dose Inconsistency in Clinical Trials: The Simulated Impact on RTOG 0617.
    Int J Radiat Oncol Biol Phys. 2021;109:1619-1626.
    PubMed     Abstract available


  283. PAN T, Lu Y, Thomas MA, Liao Z, et al
    New Data-Driven Gated PET/CT Free of Misregistration Artifacts.
    Int J Radiat Oncol Biol Phys. 2021;109:1638-1646.
    PubMed     Abstract available


    March 2021
  284. HOSKIN P
    Double the Target Volumes.
    Int J Radiat Oncol Biol Phys. 2021;109:846.
    PubMed    


  285. SHAHI J, Poon I, Ung YC, Tsao M, et al
    Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
    Int J Radiat Oncol Biol Phys. 2021;109:764-774.
    PubMed     Abstract available


    February 2021
  286. DUNNE EM, Liu M
    Postoperative Stereotactic Body Radiation Therapy, Then Observe.
    Int J Radiat Oncol Biol Phys. 2021;109:316.
    PubMed    


  287. DE BARI B
    Cautious SBRT.
    Int J Radiat Oncol Biol Phys. 2021;109:315.
    PubMed    


  288. HELM A, Tinganelli W, Simoniello P, Kurosawa F, et al
    Reduction of Lung Metastases in a Mouse Osteosarcoma Model Treated With Carbon Ions and Immune Checkpoint Inhibitors.
    Int J Radiat Oncol Biol Phys. 2021;109:594-602.
    PubMed     Abstract available


  289. NAM JK, Kim AR, Choi SH, Kim JH, et al
    Pharmacologic Inhibition of HIF-1alpha Attenuates Radiation-Induced Pulmonary Fibrosis in a Preclinical Image Guided Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2021;109:553-566.
    PubMed     Abstract available


    January 2021
  290. SALAMA JK, Giuliani ME, Robinson CG, Daly ME, et al
    Single-fraction SBRT for Early Stage NSCLC-A Viable Option in "These Uncertain Times"?
    Int J Radiat Oncol Biol Phys. 2021;109:1-4.
    PubMed    


  291. NGUYEN C, Dietz N
    Lung Mass With Massive Hemoptysis: Treatment Without Tissue Diagnosis.
    Int J Radiat Oncol Biol Phys. 2021;109:5-6.
    PubMed    


    December 2020
  292. DETAPPE A, Mathieu C, Jin C, Agius MP, et al
    Anti-MUC1-C Antibody-Conjugated Nanoparticles Potentiate the Efficacy of Fractionated Radiation Therapy.
    Int J Radiat Oncol Biol Phys. 2020;108:1380-1389.
    PubMed     Abstract available


    November 2020
  293. VASQUEZ OSORIO EM, McCallum H, Bedair A, Faivre-Finn C, et al
    Protecting the Heart: A Practical Approach to Account for the Full Extent of Heart Motion in Radiation Therapy Planning.
    Int J Radiat Oncol Biol Phys. 2020;108:1082-1090.
    PubMed     Abstract available


  294. MCWILLIAM A, Khalifa J, Vasquez Osorio E, Banfill K, et al
    Novel Methodology to Investigate the Effect of Radiation Dose to Heart Substructures on Overall Survival.
    Int J Radiat Oncol Biol Phys. 2020;108:1073-1081.
    PubMed     Abstract available


  295. GUTIONTOV SI, Pitroda SP, Weichselbaum RR
    Oligometastasis: Past, Present, Future.
    Int J Radiat Oncol Biol Phys. 2020;108:530-538.
    PubMed     Abstract available


  296. TOMA-DASU I, Moiseenko V, Purdie TG, Carlson DJ, et al
    Recent Developments in the Prediction of Clinical Outcomes Data in Radiation Oncology.
    Int J Radiat Oncol Biol Phys. 2020;108:513-517.
    PubMed    


  297. MIRSCH J, Hintz L, Maier A, Fournier C, et al
    An Assessment of Radiation Doses From Radon Exposures Using a Mouse Model System.
    Int J Radiat Oncol Biol Phys. 2020;108:770-778.
    PubMed     Abstract available


    September 2020
  298. YIN L, Xue J, Li R, Zhou L, et al
    Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:212-224.
    PubMed     Abstract available


  299. TIAN S, Switchenko JM, Buchwald ZS, Patel PR, et al
    Lung Stereotactic Body Radiation Therapy and Concurrent Immunotherapy: A Multicenter Safety and Toxicity Analysis.
    Int J Radiat Oncol Biol Phys. 2020;108:304-313.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.